Tucatinib (Irbinitinib, ARRY-380, ONT-380, ARRY380, ONT380)，又称妥卡替尼，是一种处方药，是可口服、可逆的ATP竞争性的ErbB2 (HER2)抑制剂，IC₅₀为8 nM，抑制HER2/3的磷酸化，进而抑制下游MAPK和AKT信号传导，具有潜在的抗肿瘤活性。

参考文献

1.Moulder-Thompson S, et al. Phase 1 Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+ Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC). Clin Cancer Res. 2017 Jul 15;23(14):3529-3536.

2.P. Lee, et al. In Vivo Activity of ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2 in Combination with Trastuzumab, Docetaxel or Bevacizumab. Cancer Research (Poster Session Abstracts). 2009 Dec; 69 (24_Supplement): 5104.

冰袋运输。粉末直接保存于-20℃，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。